Published in J Immunol on November 13, 2009
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
NKG2D ligands as therapeutic targets. Cancer Immun (2013) 1.26
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res (2011) 1.05
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol (2012) 1.01
Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol (2011) 0.97
NK cells: immune cross-talk and therapeutic implications. Immunotherapy (2011) 0.96
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther (2011) 0.95
Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Res Treat (2013) 0.92
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol (2013) 0.92
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol (2013) 0.90
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology (2013) 0.88
NKG2D CARs as cell therapy for cancer. Cancer J (2014) 0.87
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn) (2015) 0.83
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev (2017) 0.77
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget (2014) 0.77
Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy. Mol Ther (2015) 0.76
Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles. Nanotechnology (2014) 0.75
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. J Cell Physiol (2016) 0.75
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. J Immunol (2016) 0.75
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist (2016) 0.75
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8(+) T cells. Sci Rep (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol (2008) 3.70
Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev (2008) 3.67
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol (2007) 2.89
Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J Exp Med (2005) 2.76
A novel population of Gr-1+-activated macrophages induced during acute toxoplasmosis. J Leukoc Biol (2003) 2.29
Regulation of B1 cell migration by signals through Toll-like receptors. J Exp Med (2006) 2.11
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev (2007) 1.55
PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol (2007) 1.47
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood (2005) 1.45
The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev (2008) 1.43
B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol (2008) 1.42
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res (2006) 1.39
The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol (2003) 1.33
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol (2008) 1.32
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol (2008) 1.27
NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol (2008) 1.26
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res (2007) 1.23
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res (2007) 1.16
Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma (2008) 1.16
Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol (2008) 1.12
Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep (2005) 1.07
Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv Exp Med Biol (2007) 1.06
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol (2009) 1.00
Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol (2008) 0.97
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer (2006) 0.91
Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park) (2005) 0.85
Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br J Cancer (2005) 0.77
Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev (2005) 3.01
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Control of murine gammaherpesvirus infection is independent of NK cells. Eur J Immunol (2005) 1.57
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood (2005) 1.45
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res (2006) 1.39
Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J Immunol (2009) 1.32
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol (2008) 1.32
Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol (2007) 1.30
NKG2D ligands as therapeutic targets. Cancer Immun (2013) 1.26
Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res (2007) 1.23
Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta. J Leukoc Biol (2004) 1.17
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res (2007) 1.16
Unique characteristics of NK cells throughout the human female reproductive tract. Clin Immunol (2007) 1.11
Evolution of non-cytotoxic uterine natural killer cells. Am J Reprod Immunol (2008) 1.07
A live diarrheal vaccine imprints a Th2 cell bias and acts as an anti-inflammatory vaccine. J Immunol (2005) 1.06
TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. J Immunol (2006) 1.05
Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol (2006) 1.05
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res (2011) 1.05
IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol (2008) 1.04
NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J Immunol (2007) 1.02
Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol (2012) 1.01
Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. Exp Cell Res (2006) 1.01
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol (2009) 1.00
Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12. J Virol (2009) 0.99
Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol (2008) 0.99
An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol (2012) 0.95
NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunol Immunother (2006) 0.93
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol (2013) 0.92
Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int Immunopharmacol (2006) 0.91
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol (2013) 0.90
Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs. Am J Reprod Immunol (2009) 0.89
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology (2013) 0.88
Endogenous transforming growth factor-beta inhibits toll-like receptor mediated activation of human uterine natural killer cells. Am J Reprod Immunol (2006) 0.86
GFP transgenic mice show dynamics of lung macrophages. Exp Cell Res (2005) 0.84
Estradiol regulates MICA expression in human endometrial cells. Clin Immunol (2008) 0.84
Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunol Immunother (2007) 0.82
NKG2D receptor regulates human effector T-cell cytokine production. Blood (2011) 0.82
The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells. Transfusion (2014) 0.82
DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunol Immunother (2014) 0.80
Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy (2010) 0.79
Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant (2012) 0.79
TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. J Immunol (2011) 0.78
Challenges of creating effective chimeric antigen receptors for cancer therapy. Immunotherapy (2013) 0.77
Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. Front Biosci (Elite Ed) (2011) 0.77
Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles. Nanotechnology (2014) 0.75